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The circadian clock has been implicated in addiction and
several forms of depression [1, 2], indicating interactions
between the circadian and the reward systems in the brain
[3–5]. Rewards such as food, sex, and drugs influence this
system in part by modulating dopamine neurotransmission
in the mesolimbic dopamine reward circuit, including the
ventral tegmental area (VTA) and the ventral striatum (NAc).
Hence, changes in dopamine levels in these brain areas are
proposed to influence mood in humans and mice [6–10]. To
establish a molecular link between the circadian-clock mech-
anism and dopamine metabolism, we analyzed the murine
promotersofgenesencodingkeyenzymes important indopa-
minemetabolism.Wefind that transcriptionof themonoamine
oxidase A (Maoa) promoter is regulated by the clock compo-
nents BMAL1, NPAS2, and PER2. A mutation in the clock
gene Per2 in mice leads to reduced expression and activity
of MAOA in the mesolimbic dopaminergic system. Further-
more, we observe increased levels of dopamine and altered
neuronal activity in the striatum, and these results probably
lead to behavioral alterations observed in Per2 mutant mice
in despair-based tests. These findings suggest a role of circa-
dian-clock components indopaminemetabolismhighlighting
a role of the clock in regulating mood-related behaviors.
Results and Discussion
The Murine Maoa Promoter Is Regulated
by Clock Components In Vitro
We analyzed the promoter of Maoa for presence of E-box
elements. These elements serve as potential binding sites
*Correspondence: urs.albrecht@unifr.chfor heterodimers of CLOCK/BMAL1 or NPAS2/BMAL1, key
components of the circadian-clock mechanism [11]. In the
promoter of Maoa, we found E-box elements, which are con-
served among mouse, rat, and human, suggesting compara-
ble regulation of this gene in these species (Figure 1A). To
determine whether the Maoa promoter is regulated by clock
components, we cloned a 1.1 kb promoter fragment of the
murine Maoa (mMaoa) gene containing one canonical and
two noncanonical E-boxes into a luciferase reporter vector.
Cotransfection with clock components of this reporter
construct into the neuroblastoma cell line NG108-15 revealed
regulatory effects of clock proteins on the mMaoa promoter
(Figure 1B) in a concentration-dependent manner (Figure S1A
available online). Surprisingly, CLOCK/BMAL1 does not acti-
vate the mMaoa promoter in the neuroblastoma cell line
(Figure 1B) but in COS-7 monkey kidney cells (Table S1), sug-
gesting a possible involvement of cell-type-specific cofactors
in this process. Cotransfection of Cry1, a clock component of
the negative limb of the clock regulatory mechanism [12],
dampened the activation by NPAS2/BMAL1 in neuroblastoma
cells. Cotransfection of Per2 resulted in increased activation
(Figure 1B) as observed previously for the activation of the
aminolevulinate synthase 1 promoter [13]. To test whether
the conserved classical E-box is of importance in the mMaoa
promoter, we deleted it. This resulted in a shortened 0.7 kb
promoter that was still activated by NPAS2/BMAL1, however
in a strongly reduced manner, indicating functional importance
of the most 50 E-box in the 1.1 kb construct (Figures 1A and
1B). In contrast tomMaoa, neither a 1.2 kb fragment of the mu-
rinemonoamine oxidase B (mMaob) promoter (Figure S1B) nor
a 3.3 kb promoter fragment of the tyrosine hydroxylase, the
rate-limiting enzyme in dopamine synthesis (data not shown),
displayed comparable effects in our assays. Taken together,
our experiments indicate that the mMaoa promoter is prone
to specific regulation by clock components in vitro.
The MaoA Gene Is Hardwired Directly
to the Circadian Oscillator
In order to test circadian functionality of the mMaoa promoter,
we transfected the mMaoa-luciferase reporter construct into
NG108-15 neuroblastoma cells and followed its expression
by using real-time bioluminescence monitoring. After synchro-
nization with dexamethasone [14], we monitored luciferase
activity in the cell population over 4 days (Figure 1C and
Figure S1C). We observed an w24 hr oscillation of luciferase
activity with the same phase as a control reporter construct
containing four E-box elements derived from the clock-con-
trolled Dbp gene [15]. Similar results were also obtained
upon transfection of the construct into NIH 3T3 fibroblasts
cells (Figure S1C). This indicates that the mMaoa promoter is
capable of oscillating in a circadian fashion.
In a next step, we investigated the regulation of the mMaoa
promoter in vivo. We wanted to know whether BMAL1 directly
interacts with the mMaoa promoter in brain regions that
express this gene. Chromatin immunoprecipitation with
antibodies against BMAL1 revealed binding of this protein to
the promoter of mMaoa in brain tissue containing the VTA
(Figure 1D). This binding was also time dependent with
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679Figure 1. Regulation of the mMaoa Promoter by
Clock Components
(A) Schematic representation of E-boxes con-
served in human, rat, and mouse Maoa genes.
Letters E and E’ refer to sites of canonical and
noncanonical E-box elements, respectively,
serving as potential binding sites for the
BMAL1-NPAS2 heterodimer. Arrows indicate
the transcription start site.
(B) Transcriptional regulation of the mMaoa gene
by clock components in NG108-15 cells. Lucifer-
ase reporter plasmids containing either a 1.1 kb
mMaoa 50 upstream region, including the three
E-boxes (Maoa 1.1 kb) or a deletion of the canon-
ical E-box (Maoa 0.7 kb) was used for the tran-
scriptional assays. Presence (+) or absence (2)
of the reporter and expression plasmids is
shown. Each value represents the mean 6 SD
of three independent experiments with three
replicates for each experiment.
(C) Circadian oscillations of luciferase reporter
activity in dexamethasone synchronized NG108-
15 cells. Detrended, normalized time series,
each derived by averaging the bioluminescence
profiles of two independent cultures (representa-
tive experiment out of three independent experi-
ments), are shown. ‘‘pGL3’’ refers to a luciferase
reporter (gray, negative control), ‘‘pGL3_4-E-
box’’ refers to a pGL3 reporter containing four
E-boxes of the Dbp promoter (black, positive
control), ‘‘Maoa 1.1kb’’ refers to a pGL3 reporter
containing a 1.1 kb promoter fragment of the
mouse Maoa promoter (light-gray line).
(D) Binding of BMAL1 to the mMaoa promoter in mouse brain tissue collected at ZT 6 and ZT 18 as revealed by chromatin immunoprecipitation (ChIP).
BMAL1 does not bind to its own promoter (black bars, negative control, p > 0.05, ZT 6 versus ZT 18) but binds in a time-dependent fashion to themRevErba
promoter (gray bars, positive control, p < 0.05, ZT 6 versus ZT 18) and to themMaoa promoter (white bars, *p < 0.05 and **p < 0.01). Each value represents the
mean 6 SEM of three independent experiments with the p values determined by the Student’s t test.significantly more BMAL1 binding at Zeitgeber time (ZT) 6
compared to ZT 18 (p < 0.05, t test) comparable to the time-
dependent binding of BMAL1 to the promoter of Rev-erba,
a circadian-clock component (Figure 1D). The lower signal of
BMAL1 binding at the mMaoa promoter in vivo probably
reflects the fact that fewer cells in the analyzed brain region
express mMaoa in a circadian manner as compared to the
Rev-erba gene. Binding of BMAL1 is not observed in the
promoter region of the mBmal1 gene, a circadian gene that
does not regulate itself. BMAL1 binding at the mMaoa pro-
moter was also not observed in the cortex region or the liver
of the same animals (data not shown). We conclude that the
mMaoa promoter can be regulated by BMAL1 in a time-depen-
dent fashion in brain tissue containing the VTA.
Expression of Maoa Is Reduced in Per2 Mutant Mice
Per2Brdm1 mutant mice display altered responses to drugs of
abuse [2, 16], implying abnormal signaling in the mesolimbic
dopaminergic system of these animals. Therefore, we investi-
gated region-specific and time-dependent expression of
mMaoa and mMaob in the mesolimbic system including the
striatum and the VTA. We found cycling diurnal expression of
mMaoa mRNA in the VTA of wild-type animals (p < 0.01, one-
way ANOVA) with a maximum at ZT 6, whereas mMaob
expression was not cycling diurnally (Figure 2A). No diurnal
variation for both mMaoa and mMaob could be detected in
Per2Brdm1 mutant mice having a defective circadian clock
(p > 0.05, one-way ANOVA). Significantly lower mRNA levels
of Maoa were observed in these animals at ZT 6 (p < 0.05,
two-way ANOVA) (Figure 2A; for micrographs, see Figure S2).
Diurnal expression formMaoawas also observed in the ventralstriatum (NAc) for both genotypes with reduced expression in
Per2Brdm1 mutants at ZT 6 and ZT 12 (p < 0.05, two-way
ANOVA), whereas mMaob expression was not diurnal
(Figure 2B). However, mMaob expression was lower in
Per2Brdm1 mutants at ZT 18 (p < 0.01, two-way ANOVA). These
observations support our finding that the mMaoa promoter
can be regulated by clock components and that PER2 proba-
bly plays a positive role in this mechanism by increasing the
amplitude (Figures 1B, 2A, and 2B). The expression analyses
presented above indicate that mMaoa mRNA is stronger
expressed thanmMaob in parts of the mesolimbic dopaminer-
gic system, but we do not know whether this translates to the
protein level.
MAOA Activity Is Reduced and Dopamine Levels
Are Elevated in Per2 Mutant Mice
Alterations in expression of Maoa mRNA in Per2Brdm1 mutant
mice lead us to determine the total activity of MAO (MAOA
and MAOB) in the VTA. We find that it follows the mRNA
expression pattern of mMaoa with a maximum of MAO activity
at ZT 6 and a significantly cycling diurnal variation in wild-type
mice (p < 0.05, one-way ANOVA) but no variation (p > 0.05,
one-way ANOVA) and reduced activity in Per2Brdm1 mutants
(p < 0.0001, two-way ANOVA) (Figure 2C). In the striatum (com-
posed of the caudate Putamen [CPu] and the NAc), to which
the VTA projects, MAO activity was diurnal in wild-type mice
(p < 0.05, one-way ANOVA). This activity was constant in
Per2Brdm1 mutant animals (p > 0.05, one-way ANOVA). The
maximum of activity was delayed to ZT 12 in wild-type animals
(Figure 2D) compared to the maximal activity in the VTA
(Figure 2C), and activity was significantly reduced at this
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MAO Activity, and Striatal Dopamine Levels in
Wild-Type and Per2Brdm1 Mutant Mice
(A) mRNA expression of mMaoa (wild-type, black
squares; Per2Brdm1 mutant, open circles) and
mMaob (wild-type, black diamonds; Per2Brdm1
mutant, open triangles) in the VTA (n = 3 per
genotype each). Two-way ANOVA with Bonfer-
roni post test revealed for mMaoa a significant
effect between the genotypes at ZT 6 (*p < 0.05)
but no difference between genotypes for mMaob
(p > 0.05). One-way ANOVA shows a significant
variation of expression over time for mMaoa in
wild-type mice (p < 0.01) and no variation
in Per2Brdm1 animals (p > 0.05). No variation in
time was observed in both genotypes for mMaob
(p > 0.05). mMaoa was significantly more highly
expressed than mMaob in both genotypes
(p < 0.001).
(B) mRNA expression of mMaoa and mMaob in
the ventral striatum (NAc) (n = 3 per genotype
each). Two-way ANOVA with Bonferroni post
test revealed for mMaoa a significant effect on
genotype (p < 0.01) and time (p < 0.01) but no
interaction between the two (p > 0.05). Significant
differences between the genotypes at ZT 6
(*p < 0.05) and ZT 12 (*p < 0.05) were observed.
For mMaob, a significant difference between
genotypes was observed at ZT 18 (**p < 0.01).
mMaoa was significantly more highly expressed
than mMaob in both genotypes (p < 0.001).
(C) Enzymatic activity of MAO in the VTA (n = 3 per
genotype). Two-way ANOVA revealed a signifi-
cant effect on genotype (p < 0.0001) and time
(p < 0.05) and no interaction between the two
factors (p > 0.05). Bonferroni post test shows
a significant difference between genotypes at
ZT 6 (*p < 0.01) and ZT 0/24 (*p < 0.05).
One-way ANOVA shows significant variation of
enzyme activity over time in wild-type mice
(p < 0.05) and no variation in Per2Brdm1 animals
(p > 0.05).
(D) Enzymatic activity of MAO in the striatum
(CPu + NAc) (n = 3 per genotype). Two-way
ANOVA revealed a significant difference in geno-
type (p < 0.001) and time (p < 0.05) but no interac-
tion between the two (p > 0.05). Bonferroni post
test shows a significant difference between
genotypes at ZT 12 (*p < 0.001). One-way ANOVA
shows significant variation of enzyme activity
over time in wild-type mice (p < 0.05) and no
variation in Per2Brdm1 animals (p > 0.05).
(E) Dopamine/DOPAC ratio in the striatum (CPu + NAc). Two-way ANOVA revealed a significant difference in genotype (p < 0.05) and time (p < 0.01) but no
interaction between the two (p > 0.05). Bonferroni post test shows a significant difference between genotypes at ZT 0/24 (*p < 0.05). Data for ZT 0 and ZT 24
are double plotted. Values represent the mean 6 SEM.
(F) Extracellular levels of dopamine in the ventral striatum (NAc). Per2Brdm1 animals showed higher basal levels of dopamine release compared to wild-types
(p < 0,05; two-way ANOVA for repeated-measures; genotype F1, 9 = 5.4). A diurnal rhythm was observed inPer2
Brdm1 mice (p < 0.0001; one-way ANOVA; time
F47, 235 = 2.6) as well as in wild-type littermates (p < 0.0001; one-way ANOVA; time F47, 188 = 2.5). Values represent the mean6 SEM (n = 5–6 per genotype).time point inPer2Brdm1 mutant mice (Figure 2D) (p < 0.001, two-
way ANOVA). The delay of maximal MAO activity in the stria-
tum compared to maximal mMaoa mRNA expression in the
ventral striatum (NAc) might be the result of MAO activity in
the CPu contributing, besides the NAc, to the total activity in
the striatum. However, it appears that the reduced expression
levels of mMaoa in Per2Brdm1 mutants are reflected in the total
MAO activity, indicating that in the mouse striatum, dopamine
is metabolized predominantly by MAOA under basal condi-
tions. This is consistent with previous findings inMao-deficient
mice [17, 18]. Taken together, our observations indicate that
loss of functional PER2 lowers activity of MAO, which appears
to be the result of reduced expression of mMaoa. Becausedopamine is the most prominent neurotransmitter in the NAc
of the striatum, we expected an increase in the dopamine to
DOPAC ratio in this region of the brain. We found that this ratio
was significantly elevated in the striatum (CPu and NAc)
of Per2Brdm1 mutant mice (p < 0.05, two-way ANOVA)
(Figure 2E). This is consistent with our finding that MAO activity
is reduced. To investigate whether this increase can be
observed extracellularly, we performed microdialysis in the
ventral striatum (NAc). We find that under basal conditions,
dopamine release is significantly increased in Per2Brdm1
mutant animals compared to wild-type littermates (p < 0.05;
two-way ANOVA). Furthermore, we observed in both geno-
types diurnal changes in the levels of this neurotransmitter;
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681Figure 3. Depression-Resistant-like Phenotype
in Per2Brdm1 Mutant Mice and Relation to MAO
(A) Comparison of immobility in the forced-swim
test (FST) between wild-type (black bars) and
Per2Brdm1 mutant mice (white bars) at different
times (n = 6–14 per genotype). Two-way ANOVA
shows a significant effect on genotype
(p < 0.0001) but not on time (p > 0.05) and no in-
teraction between these two factors (p > 0.05).
One-way ANOVA with Bonferroni’s multiple-
comparison test reveals significant differences
between the genotypes at all time points (**p <
0.01, ***p < 0.001).
(B) Rescue of the depression-resistant-like phenotype assessed by FST in Per2Brdm1 mutant mice by blocking tyrosine hydroxylase activity with alpha-
methyl-p-tyrosine (AMPT) at ZT 6. A Student’s t test reveals significant differences after AMPT treatment (200 mg/kg) in Per2Brdm1 mutant mice compared
to basal levels and saline treatment (**p < 0.01, n = 9–12) but no significant difference (ns) to saline-treated wild-type animals.
(C) Decrease in immobility at ZT 6. Tail-suspension test (TST) performed 30 min after saline injection and the subsequent day 30 min after drug treatment with
amitriptyline (AMI) and tranylcypromine (TCP). Concentrations used for AMI were 3, 6, and 9 mg/kg body weight and for TCP 6, 9, and 12 mg/kg body weight
(n = 11–18). A Student’s t test revealed significant differences between the lowest and the highest dose for the AMI treatment in both genotypes (*p < 0.05).
For TCP treatment, only wild-type mice show a significant difference between the lowest and the highest dose (**p < 0.01). This is not the case for Per2Brdm1
mutant mice, indicating the higher sensitivity of these animals to TCP. Values represent the mean 6 SEM.these changes are in opposite phases as compared to MAO
activity in the same brain region. We conclude that loss of
functional PER2 is likely to lower MAOA activity in the striatum,
contributing to increased dopamine levels in Per2Brdm1 mutant
mice in this brain area. In contrast to Maoa-deficient mice that
show aggressive behavior and elevated serotonin levels,
we did not make these observations in Per2Brdm1 mutants
(data not shown), probably because Maoa expression is not
completely eliminated in our mutants. However, studies that
associate human MAOA with alcoholism [19, 20] highlight a
possible correlation between reduced expression of mMaoa
in Per2Brdm1 mutants and increased ethanol intake in these
animals [16].
Differences in Despair-Based Behavioral Tests
between Per2Brdm1 Mutant and Wild-Type Mice
In humans, dopamine levels are related to mood [6]. Because
Per2Brdm1 mutant mice display increased levels of this neuro-
transmitter in the striatum, we wanted to probe for behavioral
alterations by applying despair-based behavioral tests
believed to correlate with human mood disorders [21]. We
examined wild-type and Per2Brdm1 mutant mice in the Porsolt
forced-swim test (FST) and the tail-suspension test (TST).
They measure the duration of immobility occurring after expo-
sure of mice to an inescapable situation. However, they appear
to be regulated by different sets of genes and hence may result
in different outcomes [22]. These tests could be used because
basal locomotor activity in the two genotypes is not different
[2, 23]. The FST shows that Per2Brdm1 mutant mice display
significantly less immobility compared to wild-type animals
(p < 0.0001, two-way ANOVA, Figure 3A). This indicates an
increase in neurotransmitter levels in Per2Brdm1 mutants.
Because the response to cocaine [2] as well as expression
and activity levels of mMaoa was highest at ZT 6 in the VTA,
we performed all subsequent behavioral tests at ZT 6. To
examine whether the lower immobility in Per2Brdm1 mutants
is due to their elevated dopamine levels (Figure 2F), we aimed
to diminish the amount of dopamine in these animals. We
treated the mice with alpha-methyl-p-tyrosine (AMPT), a
potent inhibitor of tyrosine-hydroxylase (TH), the rate-limiting
enzyme of catecholamine synthesis, to reduce dopamine
levels. We find that AMPT increased immobility in Per2Brdm1
mutants compared to saline-treated mutants (p < 0.01, t
test), and immobility became comparable to saline-treated
wild-type mice (nonsignificant difference [ns]; Figure 3B). Weconclude that inhibition of TH leads to a behavioral rescue
of Per2Brdm1 mutants in the FST (Figure 3B) indicating an in-
volvement of dopamine (and/or other catecholamines) in
this phenotype.
In TST, we find that immobility times are not different
between the genotypes (Figure S3). Different outcomes in
these despair-based behavioral tests for mice are not unusual
[22]. However, because of the comparable behavioral base-
lines of the two genotypes, we could use the TST to titrate
MAO activity with an inhibitor in the two genotypes. Because
Per2Brdm1 mutants show less MAO activity (Figures 2C and
2D), we expected these animals to respond to lower doses
of tranylcypromine (TCP), a MAO inhibitor. In comparison
amitriptyline (AMI), a nonselective monoamine reuptake inhib-
itor mainly influencing serotonin and noradrenaline levels in
the synaptic cleft should be effective at similar doses for both
genotypes. We found these predictions to be met by intraper-
itoneal injections of AMI and TCP (Figure 3C). Both genotypes
show a similar dose-dependent decrease in immobility for
AMI, whereas Per2Brdm1 mutant mice are more sensitive to
TCP. These experiments are in agreement with the observa-
tion that mMaoa expression and MAO activity is reduced in
Per2Brdm1 mutants and therefore less inhibitor is necessary
to abolish MAO function. Taken together, these findings indi-
cate that Per2Brdm1 mutants react differently compared to
wild-types in tests believed to correlate with human mood
disorders.
Electrical Neuronal Activity Is Altered in Per2 Mutant Mice
in Response to MAO Inhibitors
To test how electrical activity is affected after treatment with
AMI and TCP in wild-type and Per2mutant mice, we measured
neuronal activity in the ventral striatum (NAc) in vivo. Multiunit
activity recordings show that wild-type and Per2Brdm1 mutant
animals react similarly to AMI (Figures 4A, 4B, and 4E). Inter-
estingly, wild-type mice do not show altered activity traces
after injection of 6 mg/kg TCP at ZT 6. In contrast, Per2mutant
mice display a strong response visible in the change of the
activity trace after TCP injection at ZT6 (Figures 4C and 4D).
It appears that neuronal activity in Per2 mutant mice is
significantly affected compared to that in wild-type animals
(p < 0.05, t test, Figure 4E). This result indicates that Per2
mutants are more sensitive to TCP than wild-type mice. This
might be the result of lower amounts of MAOA enzyme due
to a reduced expression of the mMaoa gene (Figure 2). Hence,
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to AMI and TCP Injections in Wild-Type and
Per2Brdm1 Mutant Mice
(A–D) Raw data traces show the effect of AMI or
TCP injection on multiple unit activity (MUA) in
the NAc of wild-type (WT) and Per2Brdm1 mutant
mice per 10 s. The gray background represents
lights off, whereas the white background is lights
on. Dotted lines indicate time of injection of
9 mg/kg body AMI or 6 mg/kg TCP. (A) shows
the response to AMI in a WT animal. (B) shows
the response to AMI in a Per2Brdm1 mutant
mouse. (C) shows the response to TCP in a WT
animal. (D) shows the response to TCP in a
Per2Brdm1 mutant mouse.
(E) Comparison of the reduction of NAc firing rate
in response to saline, AMI, and TCP injections
between WT (black bars) and Per2Brdm1 mutant
(white bars) mice (n = 8–11). TCP responses
were significantly different between WT and
Per2Brdm1 mutant mice (Student’s t test, *p <
0.05). Values represent the mean 6 SEM.these mice are potentially useful to screen for drugs targeting
MAOA to readjust intracerebral dopamine levels.
The behavioral and neuronal activity measurements for
Per2Brdm1 mutant mice (Figures 3 and 4 and [2]) could also
be explained by a change in the expression of the dopamine
transporter (DAT) and changes in dopamine receptors (DR1
and DR2). This seems to be unlikely because expression of
DAT is not significantly altered in Per2Brdm1 mutants
(Figure S4). Furthermore, expression of the excitatory dopa-
mine receptor DR1 is reduced, and expression of the inhibitory
dopamine receptor DR2 is elevated (Figure S4). This indicates
a compensatory response of the mutant organism to the
elevated dopamine concentrations at the level of its receptors.
Conclusions
Taken together, our results indicate a direct influence of circa-
dian-clock components on mMaoa expression and activity
in the mesolimbic dopaminergic system. In particular, PER2
appears to act as a positive factor, and its absence leads to
reduced Maoa expression and activity resulting in elevated do-
pamine levels in the ventral striatum (NAc). The behavioral alter-
ations thatareobserved inPer2mutantmicewith tests modeling
human mood disorders are probably due to the elevated dopa-
mine levels. This implies that alterations in the clock, as they oc-
cur in shift workers, pilots, and peoplesuffering from jet-lag, may
have profound consequences for brain function including mood
regulation by the mesolimbic dopaminergic system.
Supplemental Data
Experimental Procedures, four figures, and three tables are available at
http://www.current-biology.com/cgi/content/full/18/9/678/DC1/.
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